Documents
Application Sponsors
NDA 050689 | PHARMACIA AND UPJOHN | |
Marketing Status
Application Products
001 | CAPSULE;ORAL | 150MG | 1 | MYCOBUTIN | RIFABUTIN |
FDA Submissions
TYPE 1; Type 1 - New Molecular Entity | ORIG | 1 | AP | 1992-12-23 | PRIORITY |
MANUF (CMC); Manufacturing (CMC) | SUPPL | 2 | AP | 1993-07-28 | |
MANUF (CMC); Manufacturing (CMC) | SUPPL | 3 | AP | 1993-06-22 | |
MANUF (CMC); Manufacturing (CMC) | SUPPL | 4 | AP | 1995-09-08 | |
MANUF (CMC); Manufacturing (CMC) | SUPPL | 5 | AP | 1994-05-31 | |
MANUF (CMC); Manufacturing (CMC) | SUPPL | 6 | AP | 1994-06-06 | |
MANUF (CMC); Manufacturing (CMC) | SUPPL | 7 | AP | 1996-01-11 | |
LABELING; Labeling | SUPPL | 8 | AP | 1995-11-03 | STANDARD |
MANUF (CMC); Manufacturing (CMC) | SUPPL | 10 | AP | 1996-09-13 | |
LABELING; Labeling | SUPPL | 11 | AP | 2001-11-09 | STANDARD |
MANUF (CMC); Manufacturing (CMC) | SUPPL | 12 | AP | 1999-01-15 | |
LABELING; Labeling | SUPPL | 13 | AP | 2001-11-09 | STANDARD |
MANUF (CMC); Manufacturing (CMC) | SUPPL | 14 | AP | 2001-01-29 | |
LABELING; Labeling | SUPPL | 16 | AP | 2008-05-14 | STANDARD |
LABELING; Labeling | SUPPL | 18 | AP | 2014-11-13 | STANDARD |
LABELING; Labeling | SUPPL | 22 | AP | 2015-07-01 | STANDARD Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs. |
LABELING; Labeling | SUPPL | 25 | AP | 2021-03-08 | STANDARD |
LABELING; Labeling | SUPPL | 26 | AP | 2021-09-15 | STANDARD |
Submissions Property Types
ORIG | 1 | Null | 39 |
SUPPL | 2 | Null | 14 |
SUPPL | 3 | Null | 14 |
SUPPL | 4 | Null | 14 |
SUPPL | 5 | Null | 14 |
SUPPL | 6 | Null | 14 |
SUPPL | 7 | Null | 14 |
SUPPL | 10 | Null | 14 |
SUPPL | 12 | Null | 14 |
SUPPL | 14 | Null | 14 |
SUPPL | 16 | Null | 4 |
SUPPL | 18 | Null | 15 |
SUPPL | 22 | Null | 6 |
SUPPL | 25 | Null | 6 |
SUPPL | 26 | Null | 6 |
TE Codes
CDER Filings
PFIZER
cder:Array
(
[0] => Array
(
[ApplNo] => 50689
[companyName] => PFIZER
[docInserts] => ["",""]
[products] => [{"drugName":"MYCOBUTIN","activeIngredients":"RIFABUTIN","strength":"150MG","dosageForm":"CAPSULE;ORAL","marketingStatus":"Prescription","te":"","rld":"Yes","rs":"Yes"}]
[labels] => [{"actionDate":"09\/15\/2021","submission":"SUPPL-26","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2021\\\/050689s026lbl.pdf\"}]","notes":""},{"actionDate":"03\/08\/2021","submission":"SUPPL-25","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2021\\\/050689s025lbl.pdf\"}]","notes":""},{"actionDate":"07\/01\/2015","submission":"SUPPL-22","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2015\\\/050689s022lbl.pdf\"}]","notes":"Please see"},{"actionDate":"11\/13\/2014","submission":"SUPPL-18","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2014\\\/050689Orig1s018lbl.pdf\"}]","notes":""},{"actionDate":"05\/14\/2008","submission":"SUPPL-16","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2008\\\/050689s016lbl.pdf\"}]","notes":""},{"actionDate":"11\/09\/2001","submission":"SUPPL-11","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2001\\\/50689s11s13lbl.pdf\"}]","notes":""}]
[originalApprovals] => [{"actionDate":"MYCOBUTIN","submission":"RIFABUTIN","actionType":"150MG","submissionClassification":"CAPSULE;ORAL","reviewPriority":"Prescription","inserts":"[]","notes":">Yes"}]
[supplements] =>
[actionDate] => 2021-09-15
)
)